Year-end Sale % OFF 
Abstract
We developed a simple and rapid method for the determination of abemaciclib in human serum using supported liquid extraction (SLE) method for pretreatment and LC-MS/MS. Abemaciclib was extracted using SLE method with methyltert-butyl ether (MTBE) as elution buffer, and analyzed by LC-QTOF MS system, LCMS9030 (Shimadzu). Abemaciclib and fluconazole (internal standard) were detected with ESI spray in positive ionization mode, and the transition were set at 507.3/393.1629 for abemaciclib and 307.1/220.0677 for fluconazole. The retention times of abemaciclib and fluconazole were 2.76 and 2.98 min, respectively, and good linearity was obtained from 20–1,000 ng/mL for abemaciclib. The regression equation (weight = 1/x2) describing the calibration curve in human serum was y = 0.0196 x – 0.056 (R2 = 0.999), where y is the peak area ratio of abemaciclib against the IS and x is the nominal concentration of abemaciclib. The intra- and inter-assay accuracy varied between -4.3–1.7%, and the precision varied between 0.90–6.19%. The mean recovery rate of abemaciclib was 87.7 ± 4.3%, and the mean matrix factor was 1.00 ± 0.083. Our method offers speed and simplicity of sample preparation, which is one of great advantages in the analysis of clinical specimens. We believe that the present method will contribute to establishing a methodology for determining the optimal dose of abemaciclib for individual patients. Key words: abemaciclib, SLE, supported liquid extraction, quantification
Highlights
Abemaciclib is an orally administered small molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 [1]
To establish safer and more effective therapy using abemaciclib, we developed a method for the measurement of abemaciclib in human blood that can be applicable for clinical use using supported liquid extraction (SLE) method and LC-MS/MS analysis
The typical chromatograms obtained from blank pooled human serum (PHS) and from blank PHS spiked with abemaciclib (20, 200, 1,000 ng/mL as concentrations in serum) and fluconazole (14 ng/mL as concentration in serum) were shown in figure 1
Summary
Abemaciclib is an orally administered small molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 [1]. Martinez-Chavez et al reported the quantitative method of abemaciclib, palbociclib, and ribociclib in human and mouse matrices using LC-MS/MS [11] This method could not be applicable to the analysis of clinical specimens directly, because the measurement range of abemaciclib was set at 2–150 ng/mL in their study though the clinical concentration of abemaciclib in the blood is known to vary greatly and be about 50–300 ng/mL [12]. To establish safer and more effective therapy using abemaciclib, we developed a method for the measurement of abemaciclib in human blood that can be applicable for clinical use using SLE method and LC-MS/MS analysis
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
